<DOC>
	<DOCNO>NCT00788580</DOCNO>
	<brief_summary>RATIONALE : Pazopanib temsirolimus may stop growth tumor cell block enzymes need cell growth . Pazopanib may also block blood flow tumor . Giving pazopanib together temsirolimus may effective treatment advance solid tumor . PURPOSE : This phase I trial study side effect best dose temsirolimus give together pazopanib treat patient advance solid tumor .</brief_summary>
	<brief_title>S0718 Pazopanib Temsirolimus Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To investigate safety feasibility temsirolimus pazopanib give combination patient advance solid tumor . - To recommend maximum tolerate dose regimen patient . - To investigate pharmacokinetics temsirolimus alone combination pazopanib patient . - To investigate effect regimen relevant biological marker . - To preliminarily report objective response patient treat regimen . OUTLINE : This multicenter study . Patients receive temsirolimus IV 30 minute day 1 , 8,15 , 22 oral pazopanib hydrochloride daily day 4-28 course 1 day 1-28 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Blood sample obtain periodically evaluation pharmacokinetics temsirolimus pazopanib , plasma serum angiogenic cachectic factor ( e.g. , VEGF , bFGF , PlGF SDF-1 ) enzyme-linked immunosorbent assay , biological marker mTOR/PI3/Akt , Ras/MAPK , VEGFR , PDGFR , HIF-1 pathway . After completion study therapy , patient follow 28 day .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically pathologically verify cancer advanced stage effective therapy No lymphoma Measurable nonmeasurable disease Previously irradiate ( whole brain gamma knife ) brain metastasis allow provided requirement corticosteroid anticonvulsant PATIENT CHARACTERISTICS : Zubrod performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL ( without transfusion ) AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 time ULN liver metastasis present ) Bilirubin normal Serum creatinine ≤ 1.5 time ULN OR measure creatinine clearance OR calculate creatinine clearance ≥ 60 mL/min QTC interval &lt; 480 msec baseline ECG OR average QTC &lt; 480 msec baseline plus 2 additional screening ECG 's Fasting cholesterol &lt; 350 mg/dL Fasting triglycerides &lt; 400 mg/dL No uncontrolled hypertension , arterial thrombotic event , bleed therapeutic anticoagulation warfarin heparin ( include low molecular weight heparin ) within past 6 month Able swallow enteral medication No feed tube No intractable nausea vomit No gastrointestinal ( GI ) tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn , ulcerative colitis ) No history allergic reaction attribute compound similar chemical biologic composition rapamycin analog ( e.g. , sirolimus everolimus ) No know HIV positivity No uncontrolled intercurrent illness include , limited , follow : Ongoing serious active infection Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia History myocardial infarction Cerebrovascular accident within 3 month study entry Uncontrolled diarrhea Psychiatric illness social situation would limit compliance study requirement Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception , include barrier method Willing undergo pharmacokinetic ( PK ) sample blood submission PK translational medicine study PRIOR CONCURRENT THERAPY : Recovered prior therapy No prior pazopanib hydrochloride temsirolimus More 28 day since prior major surgery , chemotherapy , biologic therapy , immunotherapy More 28 day since prior investigational agent At least 14 day since prior radiotherapy No concurrent rapamycin ( sirolimus ) No concurrent enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , CYP3A4 inducer ( e.g. , rifampin St. John 's wort ) , CYP3A4 inhibit agent substrate ( e.g. , ketoconazole , diltiazem , verapamil ) No concurrent chemotherapy , hormonal therapy , radiotherapy , immunotherapy , type therapy treatment cancer protocol No live vaccine Luteinizinghormone releasinghormone agonists allow Concurrent prophylactic warfarin ( ≤ 1 mg/day ) allow Concurrent bisphosphonate erythropoietin analogue allow , deem appropriate treating physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>